Azafaros B.V. today announced that its lead asset, nizubaglustat, has been granted orphan drug designation from regulatory authorities in both the United States and the European Union for the ...
Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Taysha Gene Therapies in a report issued on ...
Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) have been assigned an average recommendation of “Buy” ...
Just four months later the company also discontinued the gangliosidosis programmes and announced big layoffs and the start of a its strategic review. Nassif said the board had devoted "substantial ...
GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is headquartered in Bethesda, Maryland.
Acetylleucine (IB-1001) is under development for the treatment of Niemann-Pick disease type C, GM1 Gangliosidosis, GM2 gangliosidosis, ataxia telangiectasia, spinocerebellar ataxia, Tay-Sachs Disease, ...
Acetylleucine (IB-1001) is under development for the treatment of Niemann-Pick disease type C, GM1 Gangliosidosis, GM2 gangliosidosis, ataxia telangiectasia, spinocerebellar ataxia, Tay-Sachs Disease, ...
After hours: January 23 at 6:16:46 PM EST Loading Chart for GANX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback